Immunome, Inc. $IMNM Shares Bought by AlphaQuest LLC

Key Points

• AlphaQuest LLC significantly increased its holdings in Immunome, Inc. by 583.6%, owning 53,788 shares valued at approximately $362,000 as of the latest report.
• Institutional investors collectively own 44.58% of Immunome, with notable increases from firms like GAMMA Investing LLC and Tower Research Capital LLC.
• Wall Street analysts maintain a consensus "Buy" rating for Immunome, with target prices ranging from $18.00 to $25.00.

AlphaQuest LLC boosted its stake in Immunome, Inc. (NASDAQ:IMNM - Free Report) by 583.6% during the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 53,788 shares of the company's stock after buying an additional 45,920 shares during the period. AlphaQuest LLC owned approximately 0.06% of Immunome worth $362,000 at the end of the most recent quarter.

Other large investors also recently bought and sold shares of the company. T. Rowe Price Investment Management Inc. increased its position in shares of Immunome by 37.4% during the first quarter. T. Rowe Price Investment Management Inc. now owns 7,554,594 shares of the company's stock valued at $50,843,000 after acquiring an additional 2,054,640 shares during the last quarter. Wellington Management Group LLP increased its holdings in Immunome by 5.1% in the 1st quarter. Wellington Management Group LLP now owns 153,011 shares of the company's stock valued at $1,030,000 after purchasing an additional 7,447 shares during the last quarter. Freestone Capital Holdings LLC purchased a new stake in Immunome in the first quarter valued at approximately $415,000. Fox Run Management L.L.C. acquired a new position in Immunome during the first quarter worth $203,000. Finally, Nuveen LLC acquired a new position in Immunome during the first quarter worth $1,615,000. Institutional investors and hedge funds own 44.58% of the company's stock.

Immunome Price Performance

Shares of Immunome stock traded down $0.23 during trading on Tuesday, hitting $9.28. 568,776 shares of the stock were exchanged, compared to its average volume of 627,134. The stock has a market cap of $807.73 million, a price-to-earnings ratio of -3.01 and a beta of 1.92. The firm's 50-day moving average price is $9.80 and its 200 day moving average price is $8.84. Immunome, Inc. has a 12-month low of $5.15 and a 12-month high of $16.73.

Immunome (NASDAQ:IMNM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported ($0.50) EPS for the quarter, beating the consensus estimate of ($0.52) by $0.02. Immunome had a negative return on equity of 76.10% and a negative net margin of 1,687.08%.The firm had revenue of $4.02 million for the quarter, compared to analyst estimates of $1.03 million. As a group, research analysts forecast that Immunome, Inc. will post -2.21 earnings per share for the current year.

Analyst Ratings Changes

IMNM has been the subject of a number of research reports. Evercore ISI started coverage on Immunome in a research note on Friday, August 22nd. They issued an "outperform" rating and a $18.00 price objective for the company. Guggenheim reaffirmed a "buy" rating and issued a $25.00 target price on shares of Immunome in a research report on Monday, August 25th. JPMorgan Chase & Co. cut their price target on shares of Immunome from $23.00 to $22.00 and set an "overweight" rating on the stock in a research note on Thursday, August 7th. Wall Street Zen raised shares of Immunome from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, Wedbush restated an "outperform" rating and issued a $21.00 price objective on shares of Immunome in a report on Thursday, August 7th. Eight research analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the company currently has a consensus rating of "Buy" and a consensus price target of $22.50.

Immunome Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.